A total of 483 CLL followed at our Center were investigated at different phases of the disease: 182 patients at the time of initial diagnosis, 240 patients with progressive disease prior to treatment and 61 patients resistant to first-or second-line treatment. All patients gave their informed consent to blood collection and to the biological analyses included in the present study according to the Declaration of Helsinki. The diagnosis of CLL was based on the presence of more than 5,000 lymphocytes/mL in the peripheral blood that expressed a classic CLL immunophenotype (CD5/CD20 
A total of 483 CLL followed at our Center were investigated at different phases of the disease: 182 patients at the time of initial diagnosis, 240 patients with progressive disease prior to treatment and 61 patients resistant to first-or second-line treatment. All patients gave their informed consent to blood collection and to the biological analyses included in the present study according to the Declaration of Helsinki. The diagnosis of CLL was based on the presence of more than 5,000 lymphocytes/mL in the peripheral blood that expressed a classic CLL immunophenotype (CD5/CD20 ) and morphology. IGHV gene analysis, CD38 and ZAP-70 antigen expression, and fluorescence in situ hybridization (FISH) analysis were performed as previously described [1] [2] [3] [4] . At the time of mutation analysis, patients studied at diagnosis had a median age of 53 years (range 29-68) and presented a median of 20.1x10 
DNA sequencing analysis of the TP53 gene
Mutation analysis of TP53 exons 5 to 8 was carried out by DNA direct sequencing on an ABI PRISM 3100 automated DNA sequence analyzer (Applied Biosystems, Foster City, CA, USA), as previously described. 5 In addition, analysis of the entire coding region of TP53 was carried out only in those cases where a discrepancy was found between p53 functional analysis and TP53 sequencing. Mutations were validated by the IARC TP53 Mutation Database 6 (version R15, November 2010) (http://www-p53.iarc.fr/Somatic.html) and the UMD TP53 Mutation Database
7
(http://p53.free.fr/Database/p53_database.html).
Chronic lymphocytic leukemia cell culture and p53 induction
One hundred and nine CLL patients from the entire cohort 17 at diagnosis, 72 at progression and 20 with chemoresistant disease were characterized for their ability to induce p53 activation. For this purpose, CLL cells were exposed to 5Gy IR and both irradiated and non-irradiated samples were cultured for 8 and 24 h in RPMI 1640 (Cambrex BioScience Verviers, Belgium) supplemented with 10% heat-inactivated fetal bovine serum (FBS, HyClone, South Logan, UT, USA), 1% L-glutamine and 1% Pen-strepto (Euro-Clone, Milan, Italy), at 37°C in the presence of 5% CO2. Healthy donor PBL were used as negative controls, while the TP53-mutated Burkitt's lymphoma B-cell line Raji, purchased from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany), as positive control.
Assessment of p53 activity by Western blot
Irradiated and non-irradiated samples after 8-h cultures were lysed in 2M Tris-HCl (pH 8), 0.5 M EDTA (pH 8), 5M sodium chloride, 0.05M sodium fluoride, 0.001M sodium orthovanadate, 10% Triton X-100 and a protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). Protein extracts were separated by SDS-PAGE and blotted on nylon membranes (Immobilon-P; Millipore, Bedford, MA, USA). After blocking in 5% milk for 1 h, the membranes were probed with a monoclonal antibody to p53 (Calbiochem-Novabiochem, La Jolla, CA, USA; 1:500). A peroxidase-conjugated secondary antibody (Pierce Biotecnology, Rockford, IL, USA; 1:10000) and the ECL system (GE Healthcare, Buckinghamshire, UK) were used for detection. As a control for protein loading, the membranes were reprobed with a monoclonal antibody to glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Chemicon, Millipore; 1:2000). Densitometric analysis was performed using the ImageJ software (NIH).
Apoptosis assay
IR-induced apoptosis was evaluated after 24-h culture using the Annexin-V technique. Briefly, CLL cells were washed in PBS and resuspended in 1xBinding buffer (10xBinding buffer: 100mM HEPES/NaOH pH 7.5, 1.4M NaCl, 25mM CaCl2) adding FITC-conjugated Annexin-V and Propidium iodide (Sigma-Aldrich CO, St Louis, MS, USA) both at a final concentration of 1 mg/mL. The mixture was incubated in the dark for 10 min at room temperature and apoptotic cells were measured by flow cytometry and the data analyzed using the CellQuest software (Becton Dickinson). DApoptosis was calculated as:
[IR-induced apoptosis − spontaneous apoptosis].
Online Supplementary Figure S1 . TP53 mutation profile of CLL patients in each phase of the disease. (A) An increased proportion of cases with microdeletions (15%) was found in patients with progressive disease and a higher incidence of nonsense mutations (27%) in chemoresistant patients. In contrast, all mutations found in patients at diagnosis were missense mutations (100%). (B) Hot spot mutations were observed exclusively in progressive and chemoresistant CLL, while transitions at CpG sites were uncommon in CLL at chemoresistance.
Statistical analysis
Box plots were generated using the statistical tools available at http: //www.physics.csbsju.edu/stats/t-test_bulk_form.html Online Supplementary Table S1 . TP53 mutation profile and biological characteristics of TP53 mutated CLL patients considered either totally or divided according to their disease phase. 
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